PaxVax, Inc. Presents Phase 1 Clinical Trial Data for Single-Dose Cholera Vaccine
11/14/2012 10:19:52 AM
MENLO PARK, Calif., & ATLANTA--(BUSINESS WIRE)--PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax’s single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta. The results were presented by the company’s collaborator, Dr. Wilbur Chen of the University of Maryland, Baltimore. The vaccine candidate, PXVX0200 (also known as CVD 103-HgR), was found to be well tolerated and immunogenic.